ProfileGDS5678 / 1422537_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 93% 95% 93% 95% 94% 93% 94% 93% 94% 94% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9185693
GSM967853U87-EV human glioblastoma xenograft - Control 27.9495893
GSM967854U87-EV human glioblastoma xenograft - Control 37.8647293
GSM967855U87-EV human glioblastoma xenograft - Control 48.8106395
GSM967856U87-EV human glioblastoma xenograft - Control 57.8640293
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.2672995
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0532194
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.9426493
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.1805194
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8732493
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9870994
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.1261894
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.2930794
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9969294